Tamoxifen (Tamoxifenum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Antineoplastic hormonal agents and hormone antagonists

"Estrogens, gestagens, their homologues and antagonists"

Included in the formulation
  • Vero-Tamoxifen
    pills inwards 
    VEROPHARM SA     Russia
  • Tamoxifen
    pills inwards 
    Orion Corporation     Finland
  • Tamoxifen
    pills inwards 
    OBOLENSKOE PHARMACEUTICAL ENTERPRISE, CJSC     Russia
  • Tamoxifen
    pills inwards 
    OZONE, LLC     Russia
  • Tamoxifen
    pills inwards 
    NORTH STAR, CJSC     Russia
  • Tamoxifen
    pills inwards 
    VALENTA PHARM, PAO     Russia
  • Tamoxifen HEXAL
    pills inwards 
    HEXAL AG     Germany
  • Tamoxifen-Ebwee
    pills inwards 
    Ebewe Pharma Gesmb.b. Nfg. KG     Austria
    • Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):

    VED

    ONLS

    АТХ:

    L.02.B.A.01   Tamoxifen

    Pharmacodynamics:

    Competitively binds to estrogen receptors without showing its own estrogen-like activity, it blocks the trophic action of estrogens by suppressing the activity of estrogen receptors followed by their degradation. It also reduces the expression of progesterone receptors.

    Has a slight stimulating effect on endometrial cells and bone tissue.

    Pharmacokinetics:

    After oral administration, up to 98% is absorbed in the gastrointestinal tract.The maximum concentration in the blood plasma is reached in 4-7 hours. The connection with plasma proteins is 99%.

    Metabolism in the liver.

    The half-life period is 14 days. Elimination with feces in the form of inactive metabolites.

    Indications:

    It is used to treat locally advanced or disseminated breast cancer with positive estrogen receptors. Used to treat endometrial cancer.

    ICD-10

    II.C50.C50   Malignant neoplasm of breast

    II.C51-C58.C54.1   Malignant neoplasm of endometrium

    Contraindications:

    Violations of liver function, individual intolerance, children under 18 years of age (no data on efficacy and safety).

    Carefully:

    Expressed violations of kidney function (creatinine clearance less than 30 ml / min), cataracts, deep vein thrombosis, hyperlipidemia, hypersensitivity.

    Pregnancy and lactation:

    Recommendations for FDA - category D. Contraindicated in pregnancy and lactation.

    Dosing and Administration:

    Inside, 20-40 mg 1-2 times a day.

    The highest daily dose: 40 mg.

    The highest single dose: 20 mg.

    Side effects:

    Central and peripheral nervous system: headache, asthenia, rarely - depression.

    The cardiovascular system: hot flashes (sensation of fever), thromboembolism.

    Digestive system: nausea, vomiting, anorexia, hepatitis.

    Dermatological reactions: rash, alopecia.

    Urinary system: fluid retention, urinary tract infection.

    Reproductive system: galactorrhea, leukorrhea, vaginal bleeding, vaginal moniliasis.

    Allergic reactions.

    Overdose:

    Cases of overdose are not described.

    Treatment is symptomatic.

    Interaction:

    Strengthens the effect of anticoagulants coumarinic series.

    Reduces the effect of anastrozole by reducing its concentration in the blood plasma.

    With simultaneous use with cytostatics, the risk of thromboembolism increases.

    Bromocriptine increases tamoxifen in blood plasma.

    Special instructions:

    Tamoxifen causes ovulation, so it is recommended that women who receive treatment receive reliable contraceptive methods.

    The drug is ineffective in the occurrence of metastases, especially in the liver.

    In the treatment it is not recommended to drive vehicles and work with moving mechanisms.

    Instructions
    Up